GeneDx Corp. (WGS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

GeneDx Corp. (WGS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

72.10

-12.91 (-15.19%)

At close: Jan 14, 2025, 3:59 PM

73.65

2.15%

Pre-market Jan 15, 2025, 07:11 AM EST

undefined% (undefined)

Bid	71
Market Cap	1.98B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.09
PE Ratio (ttm)	-23.33
Forward PE	n/a
Analyst	Strong Buy

Ask	76
Volume	2,138,268
Avg. Volume (20D)	650,621
Open	85.72
Previous Close	85.01
Day's Range	70.69 - 86.08
52-Week Range	2.85 - 98.87
Beta	undefined

About WGS

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides scien...

[Show more]

Industry Medical - Healthcare Information Services

Sector Healthcare

IPO Date Nov 4, 2020

Employees 1,000

Stock Exchange NASDAQ

Ticker Symbol WGS

Website http://www.genedx.com

Analyst Forecast

According to 5 analyst ratings, the average rating for WGS stock is "Strong Buy." The 12-month stock price forecast is $75, which is an increase of 4.03% from the latest price.

Buy 60.00%

Hold 40.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

GeneDx Corp. is scheduled to release its earnings on Feb 18, 2025, before market opens.
Analysts project revenue of $80.22M, reflecting a 39.71% YoY growth and earnings per share of 0.11, making a -115.94% decrease YoY.

Why Price Moved

1 week ago · Source

+8.29%

GeneDx shares are trading higher after TD Cowen ra... Unlock content with Pro Subscription

2 months ago · Source

+49.88%

GeneDx shares are trading higher higher after the company reported better-than-expected Q3 financial results and raised its FY24 revenue guidance.

News

2 days ago · businesswire.com

GeneDx Announces Preliminary 2024 Financial Results

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported preliminary financial results for the fourth quarter and full year of 2024.

6 days ago · businesswire.com

GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx launches new telehealth testing pathway to connect parents directly with genetic experts to increase access to exome and genome testing.

1 week ago · businesswire.com

GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, continues its investment in advancing scientific discovery through und...

1 week ago · zacks.com

GeneDx Holdings (WGS) Surges 13.2%: Is This an Indication of Further Gains?

GeneDx Holdings (WGS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre...

1 week ago · investors.com

Meta Stock, Energy Plays Lead Five Leaders Rebounding Bullishly

Meta Platforms leads five stocks flashing entries as they rebound above key moving averages within consolidations. The post Meta Stock, Energy Plays Lead Five Leaders Rebounding Bullishly appeared fir...

1 week ago · seekingalpha.com

Best-Performing Stocks Of 2024

1 week ago · businesswire.com

GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating O...

4 weeks ago · businesswire.com

GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 43rd A...

1 month ago · investors.com

This Once Ultracheap Biotech Stock Rockets 2,762%, Nears Buy Point After Big Earnings Win

Biotech stock GeneDx soared 50% after earnings on Oct. 29. Shares of the genetic testing company have soared 2,762% year to date.

1 month ago · businesswire.com

GeneDx to Participate in Upcoming Investor Conference

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in the Piper Sandler 36th Annual Healthcare Conference.

1 month ago · businesswire.com

GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, ...

2 months ago · fool.com

Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year

2 months ago · businesswire.com

New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the results of an extensive study shedding light on th...

2 months ago · businesswire.com

GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American Soci...

2 months ago · zacks.com

3 Stocks to Buy for Stellar Earnings Acceleration in November

Stocks like Snap, GeneDx Holdings and Leonardo DRS exhibit solid earnings acceleration.

2 months ago · zacks.com

Best Momentum Stocks to Buy for November 4th

WGS, CVNA and NBBK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 4, 2024.

2 months ago · zacks.com

New Strong Buy Stocks for November 4th

CFFN, VLRS, NBBK, WGS and ISBA have been added to the Zacks Rank #1 (Strong Buy) List on November 4, 2024.

2 months ago · seekingalpha.com

Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds

The precision medicine market is projected to grow from $91.72 billion in 2024 to $246.3 billion by 2033, fueled by advancements in genomic technologies. In the last year, Natera, Inc. and GeneDx Hold...

2 months ago · seekingalpha.com

GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term

GeneDx Holdings Corp. stock has risen by a scarcely believable >3,000% across the past year. The company provides exome sequencing products that can be used to search for and diagnose hundreds of gene...

2 months ago · seekingalpha.com

GeneDx Holdings Corp. (WGS) Q3 2024 Earnings Call Transcript

GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Execu...

Load More News